Real-time, 3-D microscopic tissue imaging could be a revolution for medical fields such as cancer diagnosis, minimally invasive surgery and ophthalmology. University of Illinois researchers have developed a technique to computationally correct for aberrations in optical tomography, bringing the future of medical imaging into focus.
The computational technique could provide faster, less expensive and higher resolution tissue imaging to a broader population of users. The group describes its technique this week in the online early edition of the Proceedings of the National Academy of Sciences.
"Computational techniques allow you to go beyond what the optical system can do alone, to ultimately get the best quality images and three-dimensional datasets," said Steven Adie, a postdoctoral researcher at the Beckman Institute for Advanced Science and Technology at the U. of I. "This would be very useful for real-time imaging applications such as image-guided surgery."
Aberrations, such as astigmatism or distortion, plague high-resolution imaging. They make objects that should look like fine points appear to be blobs or streaks. The higher the resolution, the worse the problem becomes. It's especially tricky in tissue imaging, when precision is vital to a correct diagnosis. . .View Full Article
"ARNI's chairman is one of the best in the world in the urology field, and the company's consortium of investors has given us a lot of validation." (4/3/14) Arno Therapeutics Inc. - The Life Sciences Report Interview with Ran Nussbaum More >
Computing the Best High-Resolution 3-D Tissue Images
Source: ScienceDaily (4/25/12)
"Real-time, 3-D microscopic tissue imaging could be a revolution for medical fields such as cancer diagnosis, minimally invasive surgery and ophthalmology."
"Positive clinical data will make CTH's APL-130277 a very attractive asset for specialty pharma or large pharma." (3/19/14) Cynapsus Therapeutics Inc. - The Life Sciences Report Interview with Stephen Ireland More >
"NEO is in the process of launching next-generation sequencing for the clinical trial market; the deal with Covance sets the stage for the company to go to the next level." (2/27/14) NeoGenomics Laboratories - The Life Sciences Report Interview with Debjit Chattopadhyay More >